O	0	10	Randomized
O	11	16	trial
O	17	19	of
B-intervention	20	24	high
I-intervention	24	25	-
I-intervention	25	29	dose
I-intervention	30	42	chemotherapy
O	43	47	with
O	48	58	autologous
O	59	69	peripheral
O	69	70	-
O	70	75	blood
O	76	80	stem
O	80	81	-
O	81	85	cell
O	86	93	support
O	94	102	compared
O	103	107	with
O	108	116	standard
O	116	117	-
O	117	121	dose
O	122	134	chemotherapy
O	135	137	in
O	138	143	women
O	144	148	with
O	149	159	metastatic
O	160	166	breast
O	167	173	cancer
O	173	174	:
O	175	179	NCIC
O	180	182	MA
O	182	183	.
O	183	185	16
O	185	186	.

O	187	189	We
O	190	199	conducted
O	200	201	a
O	202	213	multicenter
O	213	214	,
O	215	225	randomized
O	226	231	trial
O	232	234	to
O	235	242	compare
O	243	254	progression
O	254	255	-
O	255	259	free
O	260	268	survival
O	269	270	(
O	270	273	PFS
O	273	274	)
O	274	275	,
O	276	283	overall
O	284	292	survival
O	293	294	(
O	294	296	OS
O	296	297	)
O	297	298	,
O	299	302	and
O	303	310	quality
O	311	313	of
O	314	318	life
O	319	321	in
O	322	327	women
O	328	332	with
O	333	343	metastatic
O	344	350	breast
O	351	357	cancer
O	358	359	(
O	359	362	MBC
O	362	363	)
O	364	373	receiving
O	374	378	high
O	378	379	-
O	379	383	dose
O	384	396	chemotherapy
O	397	401	plus
O	402	412	autologous
O	413	417	stem
O	417	418	-
O	418	422	cell
O	423	438	transplantation
O	439	440	(
O	440	444	ASCT
O	444	445	;
O	446	450	HDCT
O	450	451	)
O	452	460	compared
O	461	465	with
O	466	474	standard
O	474	475	-
O	475	479	dose
O	480	487	therapy
O	487	488	.

O	489	496	Between
O	497	502	April
O	503	507	1997
O	508	511	and
O	512	520	December
O	521	525	2000
O	525	526	,
B-total-participants	527	530	386
B-eligibility	531	536	women
I-eligibility	537	541	with
I-eligibility	542	545	MBC
I-eligibility	546	549	and
I-eligibility	550	552	no
I-eligibility	553	558	prior
I-eligibility	559	571	chemotherapy
I-eligibility	572	575	for
I-eligibility	576	586	metastatic
I-eligibility	587	594	disease
O	595	599	were
O	600	610	registered
O	610	611	.

O	612	617	After
O	618	625	initial
O	626	634	response
O	635	637	to
O	638	651	anthracycline
O	651	652	-
O	653	655	or
O	656	662	taxane
O	662	663	-
O	663	668	based
O	669	678	induction
O	679	691	chemotherapy
O	691	692	,
B-total-participants	693	696	224
O	697	705	patients
O	706	710	were
O	711	719	randomly
O	720	728	assigned
O	728	729	:
B-intervention-participants	730	733	112
O	734	736	to
O	737	741	high
O	741	742	-
O	742	746	dose
O	747	763	cyclophosphamide
O	763	764	,
O	765	777	mitoxantrone
O	777	778	,
O	779	782	and
O	783	794	carboplatin
O	795	807	chemotherapy
O	808	811	and
O	812	816	ASCT
O	817	818	(
O	818	822	HDCT
O	822	823	)
O	823	824	,
O	825	828	and
B-control-participants	829	832	112
O	833	835	to
B-control	836	844	standard
I-control	845	852	therapy
I-control	853	854	(
I-control	854	856	ST
I-control	856	857	)
O	857	858	.

O	859	865	Median
O	866	869	age
O	870	873	was
B-age	874	876	47
I-age	877	882	years
O	883	884	(
O	884	889	range
O	889	890	,
O	891	893	25
O	894	896	to
O	897	899	67
O	900	905	years
O	905	906	)
O	906	907	.

O	908	914	Thirty
O	915	918	two
O	919	926	percent
O	927	929	of
O	930	935	women
O	936	944	randomly
O	945	953	assigned
O	954	957	had
O	958	966	estrogen
O	967	970	and
O	971	983	progesterone
O	984	992	receptor
O	992	993	-
O	993	1001	negative
O	1002	1008	breast
O	1009	1015	cancer
O	1015	1016	,
O	1017	1019	42
O	1019	1020	%
O	1021	1024	had
O	1025	1033	visceral
O	1034	1044	metastases
O	1044	1045	,
O	1046	1049	and
O	1050	1052	58
O	1052	1053	%
O	1054	1057	had
O	1058	1062	bone
O	1063	1073	metastases
O	1073	1074	.

B-outcome	1075	1083	Complete
I-outcome	1084	1093	remission
I-outcome	1094	1099	rates
O	1100	1106	before
O	1107	1113	random
O	1114	1124	assignment
O	1125	1129	were
B-iv-bin-percent	1130	1132	11
I-iv-bin-percent	1132	1133	%
O	1134	1137	for
O	1138	1143	those
O	1144	1153	receiving
O	1154	1158	HDCT
O	1159	1162	and
B-cv-bin-percent	1163	1165	12
I-cv-bin-percent	1165	1166	%
O	1167	1170	for
O	1171	1176	those
O	1177	1186	receiving
O	1187	1189	ST
O	1189	1190	.

O	1191	1196	After
O	1197	1198	a
O	1199	1205	median
O	1206	1212	follow
O	1212	1213	-
O	1213	1215	up
O	1216	1218	of
O	1219	1221	48
O	1222	1228	months
O	1228	1229	,
B-iv-bin-abs	1230	1232	79
B-outcome	1233	1239	deaths
O	1240	1244	were
O	1245	1253	observed
O	1254	1256	in
O	1257	1260	the
O	1261	1265	HDCT
O	1266	1269	arm
O	1270	1273	and
B-cv-bin-abs	1274	1276	77
O	1277	1283	deaths
O	1284	1288	were
O	1289	1297	observed
O	1298	1300	in
O	1301	1304	the
O	1305	1307	ST
O	1308	1311	arm
O	1311	1312	;
B-iv-bin-abs	1313	1318	seven
O	1319	1327	patients
O	1328	1329	(
B-iv-bin-percent	1329	1330	6
I-iv-bin-percent	1330	1331	%
O	1331	1332	)
O	1333	1335	in
O	1336	1339	the
O	1340	1344	HDCT
O	1345	1348	arm
B-outcome	1349	1353	died
I-outcome	1354	1356	as
I-outcome	1357	1358	a
I-outcome	1359	1365	result
I-outcome	1366	1368	of
I-outcome	1369	1377	toxicity
O	1377	1378	.

O	1379	1382	The
B-outcome	1383	1389	median
I-outcome	1390	1392	OS
O	1393	1396	was
B-iv-cont-median	1397	1399	24
I-iv-cont-median	1400	1406	months
O	1407	1410	for
O	1411	1414	the
O	1415	1419	HDCT
O	1420	1423	arm
O	1424	1425	(
O	1425	1427	95
O	1427	1428	%
O	1429	1431	CI
O	1431	1432	,
O	1433	1435	21
O	1436	1438	to
O	1439	1441	35
O	1442	1448	months
O	1448	1449	)
O	1450	1453	and
B-cv-cont-median	1454	1456	28
I-cv-cont-median	1457	1463	months
O	1464	1467	for
O	1468	1470	ST
O	1471	1472	(
O	1472	1474	95
O	1474	1475	%
O	1476	1478	CI
O	1478	1479	,
O	1480	1482	22
O	1483	1485	to
O	1486	1488	33
O	1489	1495	months
O	1495	1496	;
O	1497	1503	hazard
O	1504	1509	ratio
O	1510	1511	[
O	1511	1513	HR
O	1513	1514	]
O	1514	1515	,
O	1516	1517	0
O	1517	1518	.
O	1518	1519	9
O	1519	1520	;
O	1521	1523	95
O	1523	1524	%
O	1525	1527	CI
O	1527	1528	,
O	1529	1530	0
O	1530	1531	.
O	1531	1532	6
O	1533	1535	to
O	1536	1537	1
O	1537	1538	.
O	1538	1539	2
O	1539	1540	;
O	1541	1542	P
O	1543	1544	=
O	1545	1546	.
O	1546	1548	43
O	1548	1549	)
O	1549	1550	.

B-outcome	1551	1554	PFS
O	1555	1558	was
B-iv-cont-median	1559	1561	11
I-iv-cont-median	1562	1568	months
O	1569	1572	for
O	1573	1577	HDCT
O	1578	1581	and
B-cv-cont-median	1582	1583	9
I-cv-cont-median	1584	1590	months
O	1591	1594	for
O	1595	1597	ST
O	1598	1599	(
O	1599	1601	HR
O	1601	1602	,
O	1603	1604	0
O	1604	1605	.
O	1605	1606	6
O	1607	1609	in
O	1610	1615	favor
O	1616	1618	of
O	1619	1623	HDCT
O	1623	1624	;
O	1625	1627	95
O	1627	1628	%
O	1629	1631	CI
O	1631	1632	,
O	1633	1634	0
O	1634	1635	.
O	1635	1636	5
O	1637	1639	to
O	1640	1641	0
O	1641	1642	.
O	1642	1643	9
O	1643	1644	;
O	1645	1646	P
O	1647	1648	=
O	1649	1650	.
O	1650	1653	006
O	1653	1654	)
O	1654	1655	.

O	1656	1660	HDCT
O	1661	1664	did
O	1665	1668	not
O	1669	1676	improve
O	1677	1679	OS
O	1680	1682	in
O	1683	1688	women
O	1689	1693	with
O	1694	1697	MBC
O	1698	1702	when
O	1703	1707	used
O	1708	1710	as
O	1711	1724	consolidation
O	1725	1730	after
O	1731	1739	response
O	1740	1742	to
O	1743	1752	induction
O	1753	1765	chemotherapy
O	1765	1766	.
